Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. - Wikidata - awgldk - TriplyDB

Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

http://www.wikidata.org/entity/Q51008584

about

Interventions for enhancing medication adherence Interventions for enhancing medication adherence A postmenopausal osteoporotic woman losing bone mineral density despite bisphosphonates Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.Bone care nurses and the evolution of the nurse's educational function: the Guardian Angel(®) research project Bisphosphonates adherence for treatment of osteoporosis.Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.Assessment of pharmacist-led patient counseling in randomized controlled trials: a systematic review.Clinical Outcomes Used in Clinical Pharmacy Intervention Studies in Secondary Care.Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology.Complex interventions can increase osteoporosis investigations and treatment: a systematic review and meta-analysis.Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.

P2860

Q24187912-BEF27669-3306-4AC0-9DA2-93BC74DDD93F Q24243296-81E84E65-A9A8-419E-B248-0284DFCF1A6D Q34221045-30EDA712-3F62-4710-991C-05D590D01D5D Q34699332-668BA0DD-4C9E-4D33-AB81-B8C93AA0E227 Q35747560-63043264-5C23-4C3E-A0A4-4C9605EFD5A1 Q36908527-39266910-A9E0-4AA1-85BB-64445349D6A8 Q38107182-A9F4618A-428B-4906-BA3B-9EE95DC7E1E0 Q38232840-79078301-7673-4EB8-94F2-CC13AE5AD572 Q41902838-9A5E1CBA-3B3A-4009-B006-C92D505A0378 Q43767729-50F156E1-8FFC-44DB-ABEB-F95C088E7590 Q47117629-5D0B1B09-9EFC-4BA8-8930-1AA223851613 Q47771776-E93A96C8-6122-4168-89C9-E8F9F54A8438 Q48474851-01E5540E-9D08-400A-9285-BE0EE5D30A1B

P2860

Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

http://www.wikidata.org/entity/Q51008584

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Effects of pharmaceutical care ...... menopausal osteoporotic women.

@en

Effects of pharmaceutical care ...... menopausal osteoporotic women.

@nl

type

label

Effects of pharmaceutical care ...... menopausal osteoporotic women.

@en

Effects of pharmaceutical care ...... menopausal osteoporotic women.

@nl

prefLabel

Effects of pharmaceutical care ...... menopausal osteoporotic women.

@en

Effects of pharmaceutical care ...... menopausal osteoporotic women.

@nl

P1433

Q51008584-C9B95922-6ACE-4B05-BB94-624839E5A0D2

P1476

Q51008584-804A7277-D131-4909-8AD2-D1509FC4CE0B

P2093

Q51008584-0CC2D12F-563A-4503-B723-53D1477B4BE0

Q51008584-2EC73CF6-05E3-4F40-B15D-CB15EB572FD9

Q51008584-730EC30A-AB5F-410B-B198-C904E4C526B7

Q51008584-F4C5C7FD-9051-4AD7-97D6-B7AA1E15797B

P2860

Q51008584-00915242-5A3E-477B-AA20-109B0A56C66E

Q51008584-125870FD-6DD4-41EC-A4BD-CCFAEF1303C8

Q51008584-1F153273-80A1-45F0-98F1-E6261B6BBEEA

Q51008584-2B7B672F-7501-43C2-A0FF-1B97BAC783A8

Q51008584-2CE451ED-0A83-4595-B059-8A4C428225E8

Q51008584-32B8553F-6323-48A1-A8E0-0588FF28A8C4

Q51008584-4E64E0C1-E99D-4AB8-B3D4-B28236D632D1

Q51008584-54638496-F9B6-4718-828F-7A2898837C0B

Q51008584-68D85E98-1A2E-4C67-B2A9-6006448557E1

Q51008584-71A4905B-2B7A-40E7-9324-3C8D09614302

P304

Q51008584-AC80370B-37D4-422D-BECA-4114899A8E08

P31

Q51008584-45742D75-03D6-46EB-990B-F5B46783000D

P356

Q51008584-C68801D6-9716-40E0-A304-048AAB1AE664

P433

Q51008584-B93279C4-A517-4188-90A0-1AECAA29F2E7

P478

Q51008584-97004B18-721A-4817-95A5-60C0C5783467

P577

Q51008584-CC149063-C305-49D3-9B4A-EDFCF9CA5492

P698

Q51008584-C8BA8B94-A416-4992-9FB6-3EA793F10F03

P921

Q51008584-EFCF2384-0A70-4979-9AD3-95C6525FBEE7

P356

J.1365-2710.2010.01210.X

P1433

Journal of Clinical Pharmacy and Therapeutics

P1476

Effects of pharmaceutical care ...... menopausal osteoporotic women.

@en

P2093

P S M Lai

http://www.w3.org/2001/XMLSchema#string

S P Chan

http://www.w3.org/2001/XMLSchema#string

S S Chua

http://www.w3.org/2001/XMLSchema#string

Y Y Chew

http://www.w3.org/2001/XMLSchema#string

P2860

Interventions to enhance patient adherence to medication prescriptions: scientific review.

The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.

Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs.

Pharmacist scope of practice.

The concordance of self-report with other measures of medication adherence: a summary of the literature.

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.

Patient adherence to osteoporosis medications: problems, consequences and management strategies.

A systematic review of interventions by healthcare professionals on community-dwelling postmenopausal women with osteoporosis.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.

P304

557-567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2710.2010.01210.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21916908

http://www.w3.org/2001/XMLSchema#string

P921